LHV finantsportaal

Foorum Investeerimine

Börsipäev 19. oktoober

Kommentaari jätmiseks loo konto või logi sisse

  • Aktsiaturud suutsid reedel hoida pead vee pinnal ning panna punkti positiivsele nädalale. Kuigi tõusud polnud nõnda muljetavaldavad nagu nädal varem, õnnestus S&P 500 indeksil siiski trotsida nõrgemaid majandusnäitajaid ning pikendada võiduseeriat kolmandasse nädalasse, kui üheks toeavaks jõuks jäi debatt intressimäära tõstmise vajaduse üle.



    Eesti aja järgi täna varahommikul avaldatud Hiina kolmanda kvartali SKP osutus oodatust pisut paremaks. Kui analüütikute prognooside vahemik oli 6,4-6,9% ning konsensuse oma 6,8%, siis tegelikuks numbriks osutunud 6,9% kujunes kardetust pisut tugevamaks, märkides esimese kahe kvartali 7,0% kõrval siiski väikest aeglustumist.

    Sektoripõhises vaates on näha, et tööstussektoris aeglustus kasv teise kvartali 6,0% pealt 5,8% peale, samal ajal toetas majandust teenindussektor, kus kasv kiirenes 0,1pp võrra 8,6%ni (Bloombergi joonis värsket infot veel ei kajasta). Mõnevõrra on see üllatav, arvestades juunis alanud kukkumist kohalikul aktsiaturul, kuna esimesel poolaastal aitas pöörane aktsiate ostumaania suurenenud finantssektori aktiivsuse läbi lisada 7% SKP kasvu Citi andmetel tervelt 1,4 protsendipunkti.



    Paralleelselt avaldatud Hiina septembrikuu tööstustoodangu kasv aeglustus 6,1% pealt 5,7% peale (oodati 6,0%), üheksa kuu investeeringute kasv fikseeritud varadesse oli 10,3% (kaheksa kuu lõikes 10,9%), kuid jaemüügi kasv jäi stabiilseks (10,9% vs oodatud ning augustis registreeritud 10,8%), mis näitab, et aktsiaturgude korrektsioon pole tarbijatele olulist mõju avaldanud.



    Hiina majandusnäitajad pakuvad täna peamist mõtteainet, kuna nii Euroopas kui ka Ühendriikides olulisi makronäitajaid oodata pole. Ettevõtetest avaldavad oma majandustulemused teiste seas Genuine Parts, Halliburton, Hasbro, Morgan Stanley, IBM.

    16.00 Venemaa jaemüük, reaalpalga muutus, töötuse määr (september)
    17.00 USA majade ehitajate kindlustunde indeks (oktoober)

  • Morgan Stanley headline numbrid jäävad oodatust nõrgemaks

    Morgan Stanley prelim Q3 $0.34 vs $0.63 Capital IQ Consensus Estimate; revs $7.77 bln vs $8.46 bln Capital IQ Consensus Estimate
  • Gapping Up:

    In reaction to strong earnings/guidance: None this morning

    M&A news: CCG +19.7% (to be acquired by Harrison Street Real Estate Capital for $7.03/share, or ~$1.9 bln), PMCS +13.3% (MSCC proposes to acquire PMCS for $11.50/share, or ~$2.4 bln; believes its offer constitutes a 'superior proposal' over the Skyworks (SWKS) deal), DBD +3.3% (in talks with Wincor Nixdorf regarding a potential business combination valued at roughly ~$1.8 bln).

    Other news: WTW +58.9% (partners with Oprah Winfrey; Winfrey will purchase newly issued shares representing 10% of the shares outstanding, and options to acquire an additional 5% of shares), CPXX +9.6% (announces Positive Recommendation from Data And Safety Monitoring Board for Phase 3 Study Of CPX-351), ZFGN +9.1% (continued volatility), PLX +7.8% (reports positive long term data on PRX-102 for fabry disease; meaningful clinical benefit demonstrated across all key disease parameters reversal in eGFR), OCN +7.5% (to voluntarily pay down $50 mln of its Senior Secured Term Loan Facility, will have ~$476.6 mln outstanding afterwards), PLUG +5.6% (announces that its average production of oil and natural gas was 2.72 mln barrels of oil equivalent per day in September vs. 2.88 mln boed produced in August), TSYS +2.6% (receives delivery order with a $91 mln ceiling contract value from U.S. Army for SNAP deployable satellite systems sustainment), DB +2.5% (reshuffles organizational structure, various upper management roles), NAT +2.5% (favorable commentary on Friday's Mad Money), TKC +1.7% (still checking), ARRS +1.1% (provides update on pending merger with Pace, warns the closing may not occur until late December or 1Q16).

    Analyst comments: DRI +0.6% (upgraded to Buy at Maxim Group; tgt $80).


    Gapping Down:
    In reaction to disappointing earnings/guidance:
    MS -4.5% (missed on top and bottom lines; said volatility in global markets led to a difficult environment), VRX -2.3% (beats by $0.04, reports revs in-line; slightly raises Q4 guidance).

    Other news: GNCA -32.2% (reports top-line results from a Phase 2a clinical trial for GEN-004, neither of the endpoints achieved statistical significance), GLDD -15.6% (initiates a review of potential strategic alternatives, withdraws FY15 EBITDA guidance, announces the retirement of CEO Jonathan W. Berger), SDRL -5.8% (commented on investigation into Sevan Marine/Drilling, prior to SDRL acquisition), PBR -3.7% (announces that its average production of oil and natural gas was 2.72 mln barrels of oil equivalent per day in September vs. 2.88 mln boed produced in August), ZINC -2.8% (general weakness in mining), FCX -2.4% (general weakness in mining), SUNE -2.2% (still checking for anything specific), SHPG -1.1% (receives a Complete Response Letter from the FDA regarding the NDA for lifitegrast for the signs and symptoms of dry eye disease in adults), AGN -0.9% (presents results of its HARMONY study).

    Analyst comments: UBNT 3.3% (downgraded to Underperform at JMP Securities), ORCL -1.4% (downgraded to Sector Weight at Pacific Crest), TEF -1.3% (downgraded to Underperform from Neutral at Credit Suisse), STX -1.1% (downgraded to Neutral from Positive at Susquehanna).


    Briefing.com

Teemade nimekirja